Tag: Market Research Report

Metabolomics Testing: An Emerging Tool in Clinical Research

Scientific fields involved in high throughput measurement of biological molecules are referred with the suffix-omics including, nutrigenomics, transcriptomics, genomics, proteomics and metabolomics testing. Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Likewise, metabolomics testing involves the study of by products of metabolism.

Pharmaceutical Excipients – Current Scenario and Future Trends

Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently

Green Packaging: Paramount for Pharmaceutical Sector

Green Packaging in pharmaceutical secondary packaging industry plays a crucial role in ensuring the sterility and quality of a drug product, while it also provides information related to its identity and, in certain cases, dosing instructions. Pharmaceutical packaging is typically carried out under Packagingcontrolled conditions; specifically, for therapeutics that are designed for parenteral administration, fill

Alzheimers Treatment and Its Evolving Market

Alzheimer’s disease is a progressive neurological disorder characterized by the death of brain cells, eventually leading to memory loss, cognitive dysfunction and dementia. Accounting for 60-70% cases of dementia, Alzheimer’s disease is known to be the sixth leading cause of death in the US.   Presently, more than 6 million Americans of all ages are living

Cell Therapy Packaging Market – Importance and Future Potential

Over the years, the pharmaceutical industry has witnessed several advancements in drug development. It has gradually shifted from a one-drug treats all model to a more personalized approach of treatment, which involves the use of personalized cell and gene therapies for various disease indications. This shift has led to an evident change in the pharmaceutical

Progressive Supranuclear Palsy: A Tough Nut to Crack

Since John Steele, John Richardson, and Jerzy Olszewski first described Progressive Supranuclear Palsy (PSP) in 1964, the neuroscience community has been on the lookout to find a “miracle molecule” or an “elixir” that can cure patients diagnosed with this debilitating disease. With more than 2,000 research studies published so far, the progressive supranuclear palsy domain

Bioprocess Automation: A Step Towards Digital Transformation

In the era of digitalization where the world is looking forward towards automating their manufacturing process, the bioprocess industry took a while to adopt the automation technology. The biopharmaceutical industry came across several obstacles while adopting the automated technology. Examples of which include, complexity of the processes and delicacy of the living cells and organisms

Clinical Trial Design: What Does the Future Hold?

Over the years, clinical research has undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. It is worth highlighting that clinical research involves two major steps, namely study design and study reporting. Further, study design involves three key steps, theoretical design, data collection design and statistical analysis

TPD – Targeted Elimination of Disease Causing Proteins

Targeted protein degradation (TPD) is an emerging therapeutic modality that has the potential to enable the treatment of difficult-to-treat diseases. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, TPD offers a unique means to tap into the rest of the vast, unexplored proteome. Through TPD,

Continuous Manufacturing System Providers

Over the years, several industries have implemented evolutionary changes in their respective manufacturing processes. One to the most rewarding advancements in this direction, is process automation. In pharmaceutical contract manufacturing, the automation of various aspects of the production process has led to the establishment of the continuous manufacturing system providers. However, the transition to continuous

Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome is a condition in which the ovaries produce abnormal amount of androgens (males sex hormones), higher than the amount usually present in a woman with normal ovaries. The ovaries develop fluid filled sacs, known as follicles, which contain an immature egg. However, in polycystic ovary syndrome, none of the eggs mature and

Digital Therapeutics: Key Concepts to Tackle COVID-19 Pandemic

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing

Intranasal Drugs: A Deeper Look into Service Providers Landscape

The techniques used for the drug delivery are found to be have an enormous impact on the efficacy of the treatment. In fact, the slow progression of the efficacy, has suggested the need of different approaches for the effective delivery of drug (such as intranasal drugs) to the target area, along with the optimal bioavailability.

Targeted Drug Delivery System: Improving the Efficacy of Biologics

The gradual shift of healthcare industry towards the development of biologics is a well-known fact. Owing to this shift, there are over 1,000 cell and gene therapies which are being developed for the treatment of various disorders, majority of them being oncological disorders, cardiovascular disorders and neurological disorders.  Additionally, over the last decade, multiple immunotherapies

Radiopharmaceutical Manufacturing : Radioactivity In Healthcare

Fostered by partnerships between national laboratories, academia, and the pharmaceutical industry, the field of nuclear medicines and radiopharmaceutical manufacturing industry has evolved over the past few decades, in parallel with advances in imaging instrumentation, radionuclide production, and radiopharmaceutical development. Nuclear reactors and particle accelerators are presently used to produce a wide array of radionuclides for

Microbial Fermentation Companies: Impact of the Pandemic

Since the discovery of recombinant DNA technology, several types of microbes have been established as a versatile biomolecule expression system. This can be attributed to the ease of handling of microbial cell lines, which are considered less fragile (compared to cells of higher eukaryotes); rendering them a popular choice for manufacturing operations. Moreover, incremental evolution

Antibody Manufacturing Outsourcing Activities

In recent years, contract manufacturers have become an integral part of the overall biopharmaceutical market. This trend is also gaining popularity within the antibody manufacturing market, as developers are increasingly outsourcing their antibody manufacturing requirements to contract service providers. This can be attributed to the fact that employing such third-party service providers offers various advantages,

Wearable Injectors: Simplifying Chronic Disease Management

The last few years have witnessed a rising incidence of chronic illnesses across the globe. Long term clinical conditions, such as neurological disorders, cardiovascular disorders, chronic pain and oncological disorders, have been shown to impose a significant burden on the modern healthcare system and those who suffer from such diseases. It is reported that about

Human Microbiome: Significant Potential of Gut Flora

Human Microbiome Therapies are Viable Alternatives to Antibiotics, with Substantial Therapeutic Potential The term microorganisms was perceived to be synonymous to harmful, disease causing agents, until the discovery of certain beneficial microbial colonies in the human system. Currently, humans and a variety of species of bacteria, yeast and protozoa, are known to co-exist in mutually

Fill Finish Services: Impact of the Growing Biopharma Pipelines

Biopharmaceuticals represent the most rapidly growing and high-value segment of the pharmaceutical industry. Growing at an annualized rate of ~10%, the biologics contract manufacturing market stands tall with more than 5,000 biologics in development and over 300 FDA approved biologics, since 2002. Biologic drug development is characterized by high quality standards and a rapidly growing

ADME Testing Services: Rising Opportunities for Service Providers

According to the US Food and Drug Administration (USFDA), less than 10% of investigational new drug (IND) candidates progress beyond the submission of a new drug application (NDA); this implies that majority of the drug / therapy candidates fail to reach the market owing to unacceptable safety and efficacy profiles and the problems associated with

Autoinjectors: Increasing Demand for Self-Administration Devices

Over the last decade, autoinjectors have emerged as a promising therapeutic commodity for safe administration of parenteral therapies. Patients who suffer from chronic diseases, such as diabetes, rheumatoid arthritis and multiple sclerosis, often require frequent dosing of medication which poses significant inconvenience to them for visiting proper healthcare centers. Hence, autoinjector devices enable such patients

Peptide Therapeutics – A Deeper Look Into the CMO Market

The recent years have portrayed the renaissance of peptide therapeutics, as pharma industry has once again turned its attention towards the potential of therapeutic peptides. Adoption of peptide therapeutics agents have side-lined some of the earlier concerns associated with them, such as drug bioavailability enhancement, and has led to manufacturing of high-quality peptide therapeutics in

TPD: A Major Therapeutic Modality in the Coming Decade

The targeted protein degradation (TPD) approach is believed to possess the potential to unlock the undruggable proteome profile, which was traditionally considered to be inaccessible. Compared to conventional inhibition strategies, TPD offers several benefits, which include the opportunity to completely remove aberrant proteins and associated systemic malfunctions. As a result, TPD-based therapeutics have generated enthusiasm

Computer Aided Drug Discovery Providers for Large Molecules

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical contract manufacturing / biotechnology sector has been witnessed. In addition to the complexities

In Silico Drug Discovery: Drug Discovery Operations in COVID-19

The COVID-19 pandemic is predicted to throw the global economy into recession, with loss of trillions of dollars. The pharmaceutical industry cannot escape the brunt of the circumstances as well. In fact, according to a survey, 95% of healthcare industry professionals are worried about the impact the pandemic is likely to have on the industry. So far,

Immune Checkpoint Inhibitors: Another Big Opportunity

There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immune checkpoint inhibitors emerged as a highly specific and potent option to eradicate tumor cells with minimal side effects. Once the body

Ophthalmic Medication: Outsourcing has become a popular trend

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic medication development and production operations to contract service providers. Over 240 companies

Microbiome Manufacturing: Opportunities for Specialized CDMOs

What is the current development pipeline of microbiome manufacturing based live biotherapeutics? With over 85 products under preclinical and clinical development, the current development pipeline of microbiome manufacturing based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for

ANTIBODY DRUG CONJUGATES: THE RECENT APPROVALS

Antibody-Drug Conjugates (ADCs) have captured the attention of both large and small pharmaceutical companies, and academic / research institutions, engaged in the ADC contract manufacturing market. For the past few years, several failures of clinical trials were blamed for the lack of interest of some companies in this therapeutic approach. However, after a decade-long dribble

Oligonucleotides: A Response to COVID-19 Pandemic

Never before, scientists say, the universal community of researchers have put a halt to all other ongoing research and have urgently focused towards swiftly evolving health emergency. In the past few months, scientists have been repurposing their research efforts towards oligonucleotides contributing to the global effort in response to developing coronavirus preventive vaccines. For the

Neoantigen Targeted Therapies: Personalized Anti-cancer Therapy

Neoantigen Targeted Therapies Pave the Way to Personalized Anti-cancer Therapy There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immunotherapy emerged as a highly specific and potent option to eradicate tumor

Synthetic Lethality Market: Riding on the ESMO 2019 Success of PARP Inhibitors

After a strong showdown at ESMO 2019, both GSK and AstraZeneca have reignited the fight of small molecule anti-cancer drugs against the industry’s brawny immunotherapy push. Leading this fight is poly(ADP-ribose) polymerase (PARP) inhibitor, one of the leading synthetic lethality targets. These better than expected results at ESMO further validate the potential of synthetic lethality

Antibody Discovery Platform: An Opportunity Platform Providers

The rising demand for novel antibody therapy and personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody-based therapeutics. The antibody discovery platform report provides an extensive study on the current market landscape and future outlook of the antibody discovery service

Bolu Injectors: The Goldrush Continues

The large scale adoption of prefilled syringes demonstrated the growing interest in the concept of such convenient drug delivery systems. Large volume wearable injectors (also termed as bolus injectors) are advanced versions of the existing self-injection devices. The ‘Large Volume Wearable Injectors Market (3rd Edition), 2017-2027′ report features an extensive study of the current landscape and the